Eli Lilly also announced that its popular obesity drugs, Zepbound and Foundayo, will be available via the new Medicare GLP-1 ...

Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?

AHA president has asked Congress to intervene and demand HHS take a position on “drug companies’ attempts to hijack the 340B ...

By Maggie Fick BRUSSELS, June 23 (Reuters) - Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the ...

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on ...

Indianapolis-based Eli Lilly reportedly gave an unidentified 79-year-old man exclusive access to its experimental obesity and ...

It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few ...

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

A flurry of deals and lab growth is putting Greater Boston at the center of pharma giant Eli Lilly's growth strategy.

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.

The online pet retailer is not as optimistic about its prospects in 2026.

Eli Lilly is having a Total Recall moment, using cutting-edge technology to bring real, undocumented memories to life as it looks to boost awareness of Alzheimer’s disease. | Eli Lilly is having a ...